Trials / Completed
CompletedNCT00955110
Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)
An Exploratory, Single-Dose, Double-Blind, Randomized, Placebo-Controlled Crossover Study to Evaluate The Subjective and Objective Effects of Extended-Release Oxymorphone Compared to Controlled-Release Oxycodone in Healthy Non-Dependent Recreational Opioid Users
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxymorphone ER | 15mg or 30mg |
| DRUG | Oxycodone CR | 30mg or 60mg |
| DRUG | Placebo | The placebo was a sugar pill. |
| DRUG | Hydromorphone | 8 mg |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-08-07
- Last updated
- 2017-10-05
- Results posted
- 2011-07-14
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00955110. Inclusion in this directory is not an endorsement.